Biocon Ltd, in collaboration with its European partner Zentiva, has obtained decentralised procedure approval in the European Union for their complex formulation, Liraglutide, which is used to manage diabetes and support weight management.
The approval covers generic versions of Victoza, indicated for treating Type-2 Diabetes, and Saxenda, used for weight management, Biocon Ltd stated in a regulatory filing.
Victoza and Saxenda are trademarks owned by Novo Nordisk.
The Reserve Bank of India’s Monetary Policy Committee (MPC), led by Governor Sanjay Malhotra, today kept the key policy repo rate unchanged at 5.25 percent, continuing its neutral stance amid mixed macro-economic...
The Sun has been emitting a series of powerful solar flares since February 1, prompting space agencies to closely monitor potential impacts on Earth’s communication and satellite systems. Scientists have confirmed that...
The 2026 Winter Olympics, officially the XXV Olympic Winter Games, are set to take place from 6 to 22 February 2026 in Milan and Cortina d’Ampezzo, Italy, with events spread across multiple...
The United States and India have reached a significant trade agreement in early February 2026. Under the pact, the U.S. will cut tariffs on Indian goods to about 18 percent, down from...
Industry Insights Magazine delivers expert analysis, trends, and startup stories across sectors like Finance, Healthcare, Manufacturing, and Real Estate. With curated interviews, case studies, and reports, we empower professionals and entrepreneurs with actionable insights, helping them navigate change, discover opportunities, and lead confidently in today’s dynamic business landscape.
Discussion about this post